Epidermolysis Bullosa Dystrophica

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-06-08
EMA Authorised: Vyjuvek (Beremagene geperpavec) — Krystal Biotech Netherlands B.V.
The EMA authorises Vyjuvek (beremagene geperpavec) for Epidermolysis Bullosa Dystrophica.